Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.71 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323330 | 0.83 | HTR6 (1.00) | HTR6 | |
| SCHEMBL10040079 | 0.79 | HTR6 (0.55) | HTR6DRD2HTR1AHTR2AALDH1A1 | |
| SCHEMBL6549576 | 0.79 | HTR6 (0.90) | HTR6 | |
| SCHEMBL5201326 | 0.78 | HTR6 (0.62) | HTR6DRD2HTR1AHTR2AALDH1A1 | |
| SCHEMBL6548285 | 0.77 | HTR6 (0.62) | HTR6 | |
| SCHEMBL6549721 | 0.77 | HTR6 (0.62) | HTR6 | |
| SCHEMBL1136509 | 0.77 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2AALDH1A1 | |
| SCHEMBL6549834 | 0.76 | HTR6 (0.81) | HTR6 | |
| SCHEMBL27530283 | 0.76 | LMNA (0.49) | HTR6DRD2ALDH1A1L3MBTL1DRD3 | |
| SCHEMBL30999723 | 0.76 | HTR6 (0.62) | HTR6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478361-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| WO-2003072558-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| EP-1478361-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | disclosed |
| WO-2003072558-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | HTR6, TPH1, HTR5A | HTR6 1/4885DRD2 205/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.